Global Fumonisins Immunoaffinity Columns (IAC) Market Growth 2023-2029

Global Fumonisins Immunoaffinity Columns (IAC) Market Growth 2023-2029


According to our (LP Info Research) latest study, the global Fumonisins Immunoaffinity Columns (IAC) market size was valued at US$ million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Fumonisins Immunoaffinity Columns (IAC) is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.

The research report highlights the growth potential of the global Fumonisins Immunoaffinity Columns (IAC) market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Fumonisins Immunoaffinity Columns (IAC) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Fumonisins Immunoaffinity Columns (IAC). Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Fumonisins Immunoaffinity Columns (IAC) market.

Fumonisins Immunoaffinity Columns (IACs) are specialized chromatographic columns used for the extraction and purification of fumonisins from various samples. Fumonisins are a group of mycotoxins produced primarily by the fungi Fusarium verticillioides and Fusarium proliferatum. They commonly contaminate maize (corn) and related products.

Key Features:

The report on Fumonisins Immunoaffinity Columns (IAC) market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Fumonisins Immunoaffinity Columns (IAC) market. It may include historical data, market segmentation by Recovery Rate (e.g., 80% Below, 80-90%), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Fumonisins Immunoaffinity Columns (IAC) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Fumonisins Immunoaffinity Columns (IAC) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Fumonisins Immunoaffinity Columns (IAC) industry. This include advancements in Fumonisins Immunoaffinity Columns (IAC) technology, Fumonisins Immunoaffinity Columns (IAC) new entrants, Fumonisins Immunoaffinity Columns (IAC) new investment, and other innovations that are shaping the future of Fumonisins Immunoaffinity Columns (IAC).

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Fumonisins Immunoaffinity Columns (IAC) market. It includes factors influencing customer ' purchasing decisions, preferences for Fumonisins Immunoaffinity Columns (IAC) product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Fumonisins Immunoaffinity Columns (IAC) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Fumonisins Immunoaffinity Columns (IAC) market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Fumonisins Immunoaffinity Columns (IAC) market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Fumonisins Immunoaffinity Columns (IAC) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Fumonisins Immunoaffinity Columns (IAC) market.

Market Segmentation:

Fumonisins Immunoaffinity Columns (IAC) market is split by Recovery Rate and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Recovery Rate, and by Application in terms of volume and value.

Segmentation by recovery rate
80% Below
80-90%
91-100%
100% Above

Segmentation by application
Grains
Feed
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gold Standard Diagnostics Horsham
LCTech
Shimadzu
Biotez Berlin
PerkinElmer
VICAM
Ring Biotechnology
R-Biopharm AG
CHROMATIFIC
Neogen
Shandong Meizheng Bio-Tech
Pribolab
Jiangsu Suwei Micro-Biology Research
Shandong Lvdu Bio-Sciences & Technology
Jiangsu Wisdom Engineering & Technology
BIOCOMMA
Femdetection
Wuhan Huamei Wisherkon Biotech
Changsha Huaxue Biological Technology
Anavo
Shandong Vnya Bio-technology
Guanyibio
Prufunglab

Key Questions Addressed in this Report

What is the 10-year outlook for the global Fumonisins Immunoaffinity Columns (IAC) market?

What factors are driving Fumonisins Immunoaffinity Columns (IAC) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Fumonisins Immunoaffinity Columns (IAC) market opportunities vary by end market size?

How does Fumonisins Immunoaffinity Columns (IAC) break out recovery rate, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.


*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Fumonisins Immunoaffinity Columns (IAC) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Fumonisins Immunoaffinity Columns (IAC) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Fumonisins Immunoaffinity Columns (IAC) by Country/Region, 2018, 2022 & 2029
2.2 Fumonisins Immunoaffinity Columns (IAC) Segment by Recovery Rate
2.2.1 80% Below
2.2.2 80-90%
2.2.3 91-100%
2.2.4 100% Above
2.3 Fumonisins Immunoaffinity Columns (IAC) Sales by Recovery Rate
2.3.1 Global Fumonisins Immunoaffinity Columns (IAC) Sales Market Share by Recovery Rate (2018-2023)
2.3.2 Global Fumonisins Immunoaffinity Columns (IAC) Revenue and Market Share by Recovery Rate (2018-2023)
2.3.3 Global Fumonisins Immunoaffinity Columns (IAC) Sale Price by Recovery Rate (2018-2023)
2.4 Fumonisins Immunoaffinity Columns (IAC) Segment by Application
2.4.1 Grains
2.4.2 Feed
2.4.3 Others
2.5 Fumonisins Immunoaffinity Columns (IAC) Sales by Application
2.5.1 Global Fumonisins Immunoaffinity Columns (IAC) Sale Market Share by Application (2018-2023)
2.5.2 Global Fumonisins Immunoaffinity Columns (IAC) Revenue and Market Share by Application (2018-2023)
2.5.3 Global Fumonisins Immunoaffinity Columns (IAC) Sale Price by Application (2018-2023)
3 Global Fumonisins Immunoaffinity Columns (IAC) by Company
3.1 Global Fumonisins Immunoaffinity Columns (IAC) Breakdown Data by Company
3.1.1 Global Fumonisins Immunoaffinity Columns (IAC) Annual Sales by Company (2018-2023)
3.1.2 Global Fumonisins Immunoaffinity Columns (IAC) Sales Market Share by Company (2018-2023)
3.2 Global Fumonisins Immunoaffinity Columns (IAC) Annual Revenue by Company (2018-2023)
3.2.1 Global Fumonisins Immunoaffinity Columns (IAC) Revenue by Company (2018-2023)
3.2.2 Global Fumonisins Immunoaffinity Columns (IAC) Revenue Market Share by Company (2018-2023)
3.3 Global Fumonisins Immunoaffinity Columns (IAC) Sale Price by Company
3.4 Key Manufacturers Fumonisins Immunoaffinity Columns (IAC) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Fumonisins Immunoaffinity Columns (IAC) Product Location Distribution
3.4.2 Players Fumonisins Immunoaffinity Columns (IAC) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Fumonisins Immunoaffinity Columns (IAC) by Geographic Region
4.1 World Historic Fumonisins Immunoaffinity Columns (IAC) Market Size by Geographic Region (2018-2023)
4.1.1 Global Fumonisins Immunoaffinity Columns (IAC) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Fumonisins Immunoaffinity Columns (IAC) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Fumonisins Immunoaffinity Columns (IAC) Market Size by Country/Region (2018-2023)
4.2.1 Global Fumonisins Immunoaffinity Columns (IAC) Annual Sales by Country/Region (2018-2023)
4.2.2 Global Fumonisins Immunoaffinity Columns (IAC) Annual Revenue by Country/Region (2018-2023)
4.3 Americas Fumonisins Immunoaffinity Columns (IAC) Sales Growth
4.4 APAC Fumonisins Immunoaffinity Columns (IAC) Sales Growth
4.5 Europe Fumonisins Immunoaffinity Columns (IAC) Sales Growth
4.6 Middle East & Africa Fumonisins Immunoaffinity Columns (IAC) Sales Growth
5 Americas
5.1 Americas Fumonisins Immunoaffinity Columns (IAC) Sales by Country
5.1.1 Americas Fumonisins Immunoaffinity Columns (IAC) Sales by Country (2018-2023)
5.1.2 Americas Fumonisins Immunoaffinity Columns (IAC) Revenue by Country (2018-2023)
5.2 Americas Fumonisins Immunoaffinity Columns (IAC) Sales by Recovery Rate
5.3 Americas Fumonisins Immunoaffinity Columns (IAC) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Fumonisins Immunoaffinity Columns (IAC) Sales by Region
6.1.1 APAC Fumonisins Immunoaffinity Columns (IAC) Sales by Region (2018-2023)
6.1.2 APAC Fumonisins Immunoaffinity Columns (IAC) Revenue by Region (2018-2023)
6.2 APAC Fumonisins Immunoaffinity Columns (IAC) Sales by Recovery Rate
6.3 APAC Fumonisins Immunoaffinity Columns (IAC) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Fumonisins Immunoaffinity Columns (IAC) by Country
7.1.1 Europe Fumonisins Immunoaffinity Columns (IAC) Sales by Country (2018-2023)
7.1.2 Europe Fumonisins Immunoaffinity Columns (IAC) Revenue by Country (2018-2023)
7.2 Europe Fumonisins Immunoaffinity Columns (IAC) Sales by Recovery Rate
7.3 Europe Fumonisins Immunoaffinity Columns (IAC) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Fumonisins Immunoaffinity Columns (IAC) by Country
8.1.1 Middle East & Africa Fumonisins Immunoaffinity Columns (IAC) Sales by Country (2018-2023)
8.1.2 Middle East & Africa Fumonisins Immunoaffinity Columns (IAC) Revenue by Country (2018-2023)
8.2 Middle East & Africa Fumonisins Immunoaffinity Columns (IAC) Sales by Recovery Rate
8.3 Middle East & Africa Fumonisins Immunoaffinity Columns (IAC) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Fumonisins Immunoaffinity Columns (IAC)
10.3 Manufacturing Process Analysis of Fumonisins Immunoaffinity Columns (IAC)
10.4 Industry Chain Structure of Fumonisins Immunoaffinity Columns (IAC)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Fumonisins Immunoaffinity Columns (IAC) Distributors
11.3 Fumonisins Immunoaffinity Columns (IAC) Customer
12 World Forecast Review for Fumonisins Immunoaffinity Columns (IAC) by Geographic Region
12.1 Global Fumonisins Immunoaffinity Columns (IAC) Market Size Forecast by Region
12.1.1 Global Fumonisins Immunoaffinity Columns (IAC) Forecast by Region (2024-2029)
12.1.2 Global Fumonisins Immunoaffinity Columns (IAC) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Fumonisins Immunoaffinity Columns (IAC) Forecast by Recovery Rate
12.7 Global Fumonisins Immunoaffinity Columns (IAC) Forecast by Application
13 Key Players Analysis
13.1 Gold Standard Diagnostics Horsham
13.1.1 Gold Standard Diagnostics Horsham Company Information
13.1.2 Gold Standard Diagnostics Horsham Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.1.3 Gold Standard Diagnostics Horsham Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Gold Standard Diagnostics Horsham Main Business Overview
13.1.5 Gold Standard Diagnostics Horsham Latest Developments
13.2 LCTech
13.2.1 LCTech Company Information
13.2.2 LCTech Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.2.3 LCTech Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 LCTech Main Business Overview
13.2.5 LCTech Latest Developments
13.3 Shimadzu
13.3.1 Shimadzu Company Information
13.3.2 Shimadzu Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.3.3 Shimadzu Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Shimadzu Main Business Overview
13.3.5 Shimadzu Latest Developments
13.4 Biotez Berlin
13.4.1 Biotez Berlin Company Information
13.4.2 Biotez Berlin Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.4.3 Biotez Berlin Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Biotez Berlin Main Business Overview
13.4.5 Biotez Berlin Latest Developments
13.5 PerkinElmer
13.5.1 PerkinElmer Company Information
13.5.2 PerkinElmer Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.5.3 PerkinElmer Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 PerkinElmer Main Business Overview
13.5.5 PerkinElmer Latest Developments
13.6 VICAM
13.6.1 VICAM Company Information
13.6.2 VICAM Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.6.3 VICAM Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 VICAM Main Business Overview
13.6.5 VICAM Latest Developments
13.7 Ring Biotechnology
13.7.1 Ring Biotechnology Company Information
13.7.2 Ring Biotechnology Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.7.3 Ring Biotechnology Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Ring Biotechnology Main Business Overview
13.7.5 Ring Biotechnology Latest Developments
13.8 R-Biopharm AG
13.8.1 R-Biopharm AG Company Information
13.8.2 R-Biopharm AG Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.8.3 R-Biopharm AG Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 R-Biopharm AG Main Business Overview
13.8.5 R-Biopharm AG Latest Developments
13.9 CHROMATIFIC
13.9.1 CHROMATIFIC Company Information
13.9.2 CHROMATIFIC Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.9.3 CHROMATIFIC Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 CHROMATIFIC Main Business Overview
13.9.5 CHROMATIFIC Latest Developments
13.10 Neogen
13.10.1 Neogen Company Information
13.10.2 Neogen Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.10.3 Neogen Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Neogen Main Business Overview
13.10.5 Neogen Latest Developments
13.11 Shandong Meizheng Bio-Tech
13.11.1 Shandong Meizheng Bio-Tech Company Information
13.11.2 Shandong Meizheng Bio-Tech Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.11.3 Shandong Meizheng Bio-Tech Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Shandong Meizheng Bio-Tech Main Business Overview
13.11.5 Shandong Meizheng Bio-Tech Latest Developments
13.12 Pribolab
13.12.1 Pribolab Company Information
13.12.2 Pribolab Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.12.3 Pribolab Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Pribolab Main Business Overview
13.12.5 Pribolab Latest Developments
13.13 Jiangsu Suwei Micro-Biology Research
13.13.1 Jiangsu Suwei Micro-Biology Research Company Information
13.13.2 Jiangsu Suwei Micro-Biology Research Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.13.3 Jiangsu Suwei Micro-Biology Research Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Jiangsu Suwei Micro-Biology Research Main Business Overview
13.13.5 Jiangsu Suwei Micro-Biology Research Latest Developments
13.14 Shandong Lvdu Bio-Sciences & Technology
13.14.1 Shandong Lvdu Bio-Sciences & Technology Company Information
13.14.2 Shandong Lvdu Bio-Sciences & Technology Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.14.3 Shandong Lvdu Bio-Sciences & Technology Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Shandong Lvdu Bio-Sciences & Technology Main Business Overview
13.14.5 Shandong Lvdu Bio-Sciences & Technology Latest Developments
13.15 Jiangsu Wisdom Engineering & Technology
13.15.1 Jiangsu Wisdom Engineering & Technology Company Information
13.15.2 Jiangsu Wisdom Engineering & Technology Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.15.3 Jiangsu Wisdom Engineering & Technology Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Jiangsu Wisdom Engineering & Technology Main Business Overview
13.15.5 Jiangsu Wisdom Engineering & Technology Latest Developments
13.16 BIOCOMMA
13.16.1 BIOCOMMA Company Information
13.16.2 BIOCOMMA Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.16.3 BIOCOMMA Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 BIOCOMMA Main Business Overview
13.16.5 BIOCOMMA Latest Developments
13.17 Femdetection
13.17.1 Femdetection Company Information
13.17.2 Femdetection Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.17.3 Femdetection Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Femdetection Main Business Overview
13.17.5 Femdetection Latest Developments
13.18 Wuhan Huamei Wisherkon Biotech
13.18.1 Wuhan Huamei Wisherkon Biotech Company Information
13.18.2 Wuhan Huamei Wisherkon Biotech Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.18.3 Wuhan Huamei Wisherkon Biotech Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Wuhan Huamei Wisherkon Biotech Main Business Overview
13.18.5 Wuhan Huamei Wisherkon Biotech Latest Developments
13.19 Changsha Huaxue Biological Technology
13.19.1 Changsha Huaxue Biological Technology Company Information
13.19.2 Changsha Huaxue Biological Technology Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.19.3 Changsha Huaxue Biological Technology Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Changsha Huaxue Biological Technology Main Business Overview
13.19.5 Changsha Huaxue Biological Technology Latest Developments
13.20 Anavo
13.20.1 Anavo Company Information
13.20.2 Anavo Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.20.3 Anavo Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Anavo Main Business Overview
13.20.5 Anavo Latest Developments
13.21 Shandong Vnya Bio-technology
13.21.1 Shandong Vnya Bio-technology Company Information
13.21.2 Shandong Vnya Bio-technology Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.21.3 Shandong Vnya Bio-technology Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Shandong Vnya Bio-technology Main Business Overview
13.21.5 Shandong Vnya Bio-technology Latest Developments
13.22 Guanyibio
13.22.1 Guanyibio Company Information
13.22.2 Guanyibio Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.22.3 Guanyibio Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 Guanyibio Main Business Overview
13.22.5 Guanyibio Latest Developments
13.23 Prufunglab
13.23.1 Prufunglab Company Information
13.23.2 Prufunglab Fumonisins Immunoaffinity Columns (IAC) Product Portfolios and Specifications
13.23.3 Prufunglab Fumonisins Immunoaffinity Columns (IAC) Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Prufunglab Main Business Overview
13.23.5 Prufunglab Latest Developments
14 Research Findings and Conclusion

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings